Weight Loss Interventions Cut Cardiometabolic Risk for People on Antipsychotics, Randomized Trial Shows

What the Study Found

People with serious mental illness (SMI), including schizophrenia, die earlier than the general population. That much has been established. What has been harder to nail down is whether structured lifestyle interventions can actually move the needle for a population already dealing with significant barriers to health.

A 2015 randomized controlled trial published in the American Journal of Psychiatry, reviewed by Tanya Park and Bernadette Workun of the University of Alberta Faculty of Nursing in Evidence-Based Mental Health, tested exactly that. The trial was multisite, parallel two-arm, and randomized. This is the gold standard design for evaluating whether an intervention actually works rather than just correlating with better outcomes.

The program studied was called STRIDE: a weight loss and lifestyle intervention built specifically for individuals taking antipsychotic medications. Researchers Christine Green, Bobbi Yarborough, Michael Leo, and colleagues ran the trial, recruiting participants in community mental health settings.

Why This Population Has Higher Risk

Antipsychotic medications are effective at managing symptoms of schizophrenia and other serious mental illnesses. They are also well-documented drivers of weight gain and metabolic disruption. Combined with the other risk factors common in this population—sedentary lifestyle, poor nutrition access, higher rates of smoking, and limited routine medical care—the result is elevated rates of metabolic syndrome, cardiovascular disease, and type 2 diabetes.

According to the Park and Workun review in Evidence-Based Mental Health, life expectancy for people with SMI is measurably shorter than for those without. The cardiometabolic burden is a primary reason why.

This is not a political problem, it is a systems problem. Psychiatric care is siloed from primary care in most delivery models, which means a psychiatrist manages the mental illness while the metabolic consequences of treatment go unaddressed elsewhere or nowhere.

The Case for Skepticism

The strongest legitimate concern about studies like this one is generalizability and sustainability. Randomized trials conducted in controlled research settings with motivated participants and dedicated research staff do not always translate to real-world community mental health programs, which are routinely underfunded and understaffed. Critics of lifestyle intervention research in psychiatric populations argue that the structural barriers—poverty, housing instability, transportation—make long-term adherence unrealistic for many patients, no matter how well-designed the protocol.

A trial showing short-term weight loss or metabolic improvement does not automatically mean a scalable, durable public health solution exists.

The Park and Workun review acknowledges the prior evidence base was thin enough that additional trials specifically targeting this population were needed. STRIDE was designed to address that gap with a more rigorous design than earlier attempts.

What the Results Show

The STRIDE trial, according to the Park and Workun summary published in Evidence-Based Mental Health on October 8, 2015, found results supporting weight loss and lifestyle interventions as viable tools for people on antipsychotic medications. This adds to but does not complete the evidence base.

For clinicians, the implication is that prescribing an antipsychotic without monitoring or addressing metabolic consequences is not best practice. For health systems, it raises the question of whether lifestyle intervention programs should be embedded in psychiatric care rather than treated as optional add-ons.

For policymakers and insurers, the relevant unresolved question is straightforward: if structured lifestyle interventions reduce cardiometabolic risk in SMI patients and thereby reduce downstream cardiovascular and diabetes costs, what is the cost-benefit case for covering them, and who pays for integration into existing psychiatric care models? That calculation has not been settled as of June 2026.